Personalized Rituximab Treatment Based on Artificial Intelligence in

Status Not yet recruiting

Clinical Trial Summary

Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. The course of this disease is highly variable from one individual to another, ranging from spontaneous remission to progressive chronic kidney disease. The identification of autoantibodies - e.g., the phospholipase A2 receptor type 1 (PLA2R1) - has promoted the use of immunosuppressive drugs such as rituximab which is now a safe and effective first-line treatment for the management of membranous nephropathy. However, up to 40% of patients do not respond to a first course of rituximab treatment. In nephrotic patients, due to urinary drug loss, rituximab blood level is lower than in other autoimmune diseases treated with rituximab without proteinuria. This high urinary drug loss decreases the drug exposure, potentially explaining why rituximab regimen with low dose infusions (375 mg/m2) did not demonstrate efficacy after month-6 compared to a non-immunosuppressive antiproteinuric treatment in a previous study. In contrast, a regimen of two 1-g infusions two weeks apart was associated with a significantly greater remission rate after 6 months. Recently, the investigators have shown that after two 1-g rituximab infusions, the rituximab blood level 3 months after the first rituximab infusion, was correlated with the likelihood of remission after 6 and 12 months of the rituximab treatment. Patients with positive rituximab blood level 3 months after treatment had a higher chance of remission at month-6 and at month-12 than patients with an undetectable rituximab level at month-3. Nowadays, machine learning algorithms are increasingly used in medicine, especially in pharmacology, to predict the exposure to a drug, the initial dose to administer or the interval between two infusions. The objective of this study is to use a machine learning algorithm predicting the risk of having an undetectable residual level of rituximab 3 months after treatment, in order to propose a personalized treatment management with early additional doses of rituximab for the patients at risk.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06341205
Study type	Interventional
Source	Centre Hospitalier Universitaire de Nice
Contact	Barbara SEITZ-POLSKI, MD, PhD
Phone	+33492038828
Email	seitz-polski.b@chu-nice.fr
Status	Not yet recruiting
Phase	Phase 3
Start date	September 1, 2024
Completion date	September 30, 2031

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04095156` - Autoreactive B Cells in Membranous Nephropathy
Terminated	`NCT05162066` - BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)	Phase 2
Active, not recruiting	`NCT04893096` - MOR202 for Refractory MN	Phase 2
Completed	`NCT00405340` - Rituximab in the Treatment of Idiopathic Membranous Nephropathy	Phase 0
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Active, not recruiting	`NCT04652570` - Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy	Phase 1/Phase 2
Recruiting	`NCT03929887` - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting	`NCT03949855` - Belimumab With Rituximab for Primary Membranous Nephropathy	Phase 2
Not yet recruiting	`NCT06242327` - An Outcome Analysis of Primary Membranous Nephropathy
Completed	`NCT00983034` - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy	N/A
Completed	`NCT03025828` - Adrenocorticotropic Hormone in Membranous Nephropathy	Phase 4
Recruiting	`NCT05732402` - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases	Phase 1/Phase 2
Enrolling by invitation	`NCT04571658` - NEPTUNE Match Study
Recruiting	`NCT05894512` - Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Not yet recruiting	`NCT05941845` - Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy	Phase 2
Completed	`NCT00518219` - To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)	Phase 4
Completed	`NCT02199145` - Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy	N/A
Not yet recruiting	`NCT04326218` - Immunopathological Analysis in a French National Cohort of Membranous Nephropathy	N/A
Active, not recruiting	`NCT03453619` - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies	Phase 2
Completed	`NCT01955187` - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) — iRITUX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms